CAS 863288-34-0

CJC 1295

Description :

CJC-1295 est un peptide synthétique qui fonctionne comme un analogue de l'hormone de libération de l'hormone de croissance (GHRH). Il est principalement utilisé dans des contextes de recherche pour étudier ses effets sur la sécrétion de l'hormone de croissance et ses applications thérapeutiques potentielles. CJC-1295 se caractérise par sa capacité à stimuler la glande pituitaire à libérer l'hormone de croissance, ce qui peut entraîner une augmentation de la masse musculaire, une perte de graisse et une amélioration de la récupération. Le peptide a une longue demi-vie en raison de sa modification, ce qui permet une libération soutenue et une activité prolongée dans le corps. Il est généralement administré par injection sous-cutanée. CJC-1295 est souvent étudié dans le contexte du vieillissement, de la musculation et des troubles métaboliques, bien que son utilisation chez l'homme en dehors de la recherche ne soit pas approuvée par les agences réglementaires. Comme pour tout peptide, la pureté, la posologie et la voie d'administration sont essentielles à son efficacité et à sa sécurité. Les chercheurs doivent respecter les directives éthiques et les réglementations lors de la manipulation et de l'étude de ce composé.

Formule : Unspecified

Synonymes :

• <span class="text-smallcaps">L</smallcap>-Lysinamide, <smallcap>L</smallcap>-tyrosyl-<smallcap>D</smallcap>-alanyl-<smallcap>L</smallcap>-α-aspartyl-<smallcap>L</smallcap>-alanyl-<smallcap>L</smallcap>-isoleucyl-<smallcap>L</smallcap>-phenylalanyl-<smallcap>L</smallcap>-threonyl-<smallcap>L</smallcap>-glutaminyl-<smallcap>L</smallcap>-seryl-<smallcap>L</smallcap>-tyrosyl-<smallcap>L</smallcap>-arginyl-<smallcap>L</smallcap>-lysyl-<smallcap>L</smallcap>-valyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-alanyl-<smallcap>L</smallcap>-glutaminyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-seryl-<smallcap>L</smallcap>-alanyl-<smallcap>L</smallcap>-arginyl-<smallcap>L</smallcap>-lysyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-glutaminyl-<smallcap>L</smallcap>-α-aspartyl-<smallcap>L</smallcap>-isoleucyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-seryl-<smallcap>L</span>-arginyl-N⁶-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-
• <span class="text-smallcaps">L</smallcap>-Tyrosyl-<smallcap>D</smallcap>-alanyl-<smallcap>L</smallcap>-α-aspartyl-<smallcap>L</smallcap>-alanyl-<smallcap>L</smallcap>-isoleucyl-<smallcap>L</smallcap>-phenylalanyl-<smallcap>L</smallcap>-threonyl-<smallcap>L</smallcap>-glutaminyl-<smallcap>L</smallcap>-seryl-<smallcap>L</smallcap>-tyrosyl-<smallcap>L</smallcap>-arginyl-<smallcap>L</smallcap>-lysyl-<smallcap>L</smallcap>-valyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-alanyl-<smallcap>L</smallcap>-glutaminyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-seryl-<smallcap>L</smallcap>-alanyl-<smallcap>L</smallcap>-arginyl-<smallcap>L</smallcap>-lysyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-glutaminyl-<smallcap>L</smallcap>-α-aspartyl-<smallcap>L</smallcap>-isoleucyl-<smallcap>L</smallcap>-leucyl-<smallcap>L</smallcap>-seryl-<smallcap>L</smallcap>-arginyl-N⁶-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-<smallcap>L</span>-lysinamide
• Cjc 1295
• L-Tyrosyl-D-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-arginyl-N6-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-L-lysinamide
• L-Lysinamide, L-tyrosyl-D-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-arginyl-N6-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-

CJC-1295

CAS : 863288-34-0

Formule : C₁₅₂H₂₅₂N₄₄O₄₂

Degré de pureté : 95%~99%

Couleur et forme : White to Off-white Powder

Masse moléculaire : 3367.897

Ref: BP-BPPG019

CJC-1295

CAS : 863288-34-0

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Degré de pureté : Min. 95%

Ref: 3D-FC138107